Atrasentan (hydrochloride)

Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC50 of 0.0551 nM for ETA[1].

Product Specifications

CAS Number

[195733-43-8]

Product Name Alternative

ABT-627 (hydrochloride) ; (+) -A 127722 (hydrochloride) ; A-147627 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Endothelin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Atrasentan-hydrochloride.html

Purity

99.82

Solubility

0.1 M HCl : < 1 mg/mL (ultrasonic; warming; adjust pH to 1 with HCl; heat to 60°C) |DMSO : 28.57 mg/mL (ultrasonic) |H2O : 0.5 mg/mL (ultrasonic; warming; adjust pH to 4 with HCl; heat to 60°C)

Smiles

O=C([C@H]1[C@H](C2=CC=C(OC)C=C2)N(CC(N(CCCC)CCCC)=O)C[C@@H]1C3=CC=C(OCO4)C4=C3)O.Cl

Molecular Formula

C29H39ClN2O6

Molecular Weight

547.08

Precautions

H302, H315, H319, H335

References & Citations

[1]Yuyama H, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498 (1-3) :171-7.|[2]Banerjee S, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 combination in prostate cancer. Cancer Res. 2007 Apr 15;67 (8) :3818-26.|[3]Weiss J, et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol. 2011 Oct;68 (4) :1093-8.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Department Veterinary Clinical Medicine. University of Illinois. 2015.|J Vet Intern Med. 2015 Nov;29 (6) :1584-94.|Mol Immunol. 2019 Oct:114:10-18.|Commun Biol. 2022 Jul 28;5 (1) :750.|Eur J Pharmacol. 2019 Jun 5:852:142-150.|J Cell Mol Med. 2025 Apr;29 (8) :e70547.